KIT and cutaneous melanoma: Thus, monoclonal antibodies such as imatinib, sunitinib, dasatinib, nilotinib (for c-kit mutations) could have been a promising option due to a large number of c-kit mutations, but the results are not as good as in the case of cutaneous melanoma.